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A multi-bond forming, three-step tandem process involving a palladium(II)-catalysed Overman 
rearrangement and a ring closing metathesis reaction has been utilised for the efficient synthesis of a 
2,3,6,7-tetrahydro-3-amidoazepine. Substrate directed epoxidation or dihydroxylation of this synthetic 
intermediate has allowed the diastereoselective synthesis of hydroxylated 3-aminoazepanes including the 
syn-diastereomer of the balanol core. Asymmetric synthesis of the 2,3,6,7-tetrahydro-3-amidoazepine 10 
motif was also achieved using a chiral palladium(II)-catalyst during the Overman rearrangement. 
Introduction 
The azepane ring system is an important structural motif found in 
many pharmaceutically active compounds and natural products.1 
Amino-substituted azepane rings in particular, make up the core 15 
of several important natural products and medicinal agents such 
as (–)-balanol (1), a metabolite of the fungi Verticillium 
balanoides and a potent inhibitor of human protein kinase C 
(Fig.1).2 Other important aminoazepanes include azelastine (2),3 a 
selective histamine antagonist and zilpaterol (3), a β-adrenergic 20 
agonist used as a feed additive for cattle.4 Due to the interest in 
using amino-substituted azepanes as pharmacologically active 
building blocks and as conformationally constrained 
peptidomimetics,5 there has been much focus on developing 
methods for their synthesis.6,7 For example, Braga and co-25 
workers prepared a trihydroxylated aminoazepane from D-
glucitol via an aziridine ring opening reaction,7c while 
Würdemann and Christoffers utilised an intramolecular 1,3-
dipolar cycloaddition between a nitrone and an allylic amine to 
generate a cis-5-aminoazepan-3-ol.7e Most synthetic methods 30 
developed for the preparation of aminoazepanes have focused on 
the generation of the trans-3-amino-4-hydroxyazepane core of 
balanol (1)8 and include samarium iodide mediated cyclisation of 
oxime ethers8b,8c as well as ring closing metathesis (RCM) of 
amino-substituted dienes to form the azepane ring system.8d,8e, 8h,8i  35 
 While many of these synthetic methods allow the efficient 
stereoselective synthesis of amino-substituted azepane rings, they 
all rely on traditional single-step transformations that require their 
own set of reagents, solvents and conditions as well as the yield 
reducing isolation and purification of each intermediate. Cascade, 40 
domino or tandem processes overcome many limitations of 
single-step transformations and allow the formation of multiple 
bonds and molecular complexity, all in a single pot operation.9 
We now report the efficient preparation of a 2,3,6,7-tetrahydro-3-
amidoazepine using a multi-bond forming, three-step tandem 45 
process. We also demonstrate how this flexible synthetic 
intermediate can be subjected to substrate directed oxidation 
reactions for the diastereoselective preparation of hydroxylated 3-
aminoazepanes including the syn-diastereomer of the balanol 
core. 50 
 
 
 
 
 55 
 
 
 
 
 60 
 
 
 
 
Fig. 1 Structures of aminoazepane containing compounds. 65 
Results and discussion 
Our synthesis of hydroxylated 3-aminoazepanes is outlined in 
Scheme 1. It was proposed that allylic alcohol 5 could be easily 
generated using inexpensive, readily available 2-aminoethanol 
(6). A three-step tandem process involving a palladium(II)-70 
catalysed Overman rearrangement and a RCM reaction was then 
envisaged for the preparation of 2,3,6,7-tetrahydro-3-
amidoazepine 4. Subsequent stereoselective oxidation of the 
alkene using the trichloroacetamide substituent as a directing 
group would lead to the hydroxylated 3-aminoazepanes. 75 
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Scheme 1 Proposed route to hydroxylated 3-aminoazepanes. 10 
 Initially, a synthetic route was developed for the efficient 
preparation of allylic alcohol 5 (Scheme 2), the substrate for the 
tandem process. 2-Aminoethanol (6) was coupled with 4-bromo-
1-butene in the presence of sodium iodide to give 7 in 
quantitative yield. Silyl protection of the primary alcohol then 15 
allowed Boc-protection of the secondary amine. Removal of the 
silyl protecting group under standard conditions gave alcohol 9 
which was then subjected to a one-pot Swern oxidation and 
Horner-Wadsworth-Emmons reaction under Masamune-Roush 
conditions.10,11 This gave exclusively E-α,β-unsaturated ester 11 20 
in 94% yield over the two steps. DIBAL-H reduction of 11 was 
attempted but gave E-allylic alcohol 5 in only 37% yield along 
with a complex mixture of compounds. It is well-known that α,β-
unsaturated esters containing adjacent heteroatoms can undergo 
competing 1,4-addition rather than 1,2-reduction due to 25 
complexation of the metal hydride with the heteroatom.12 This 
can be overcome using the Moriwake modification that involves 
addition of a Lewis acid to protect the heteroatom.12 However, 
attempted reduction of 11 using DIBAL-H in the presence of 
boron trifluoride diethyl etherate gave 11 in only a slightly 30 
improved yield of 41%. Due to the issues associated with 
reduction of 11, a more efficient route to E-allylic alcohol 5 was 
achieved via α,β-unsaturated aldehyde 12. Primary alcohol 9 was 
subject to a Swern oxidation which gave aldehyde 10 in 94% 
yield. Wittig reaction of 10 with 35 
(triphenylphosphoranylidene)acetaldehyde followed by reduction 
of the aldehyde moiety with sodium borohydride reduction gave 
E-allylic alcohol 5 in 88% yield. This seven-step synthesis was 
particularly amenable to scale-up (~5 g) giving allylic alcohol 5 
in 53% overall yield from 2-aminoethanol (6).  40 
 Allylic alcohol 5 was then subjected to the three-step tandem 
process for the preparation of 2,3,6,7-tetrahydro-3-amidoazepine 
4 (Scheme 3).13 Allylic alcohol 5 was converted to allylic 
trichloroacetimidate 13 under standard conditions, followed by 
rearrangement with bis(acetonitrile)palladium(II) chloride.14,15 As 45 
part of the one-pot tandem process, 14 was initially treated with 
Grubbs 1st generation catalyst.16 However, this required a RCM 
reaction time of 96 hours giving 2,3,6,7-tetrahydro-3-
amidoazepine 4 in 49% from 5. The RCM step of the tandem 
process was improved substantially using Grubbs 2nd generation 50 
catalyst,17 which gave 2,3,6,7-tetrahydro-3-amidoazepine 4 after 
only 12 hours and in 79% overall yield. 
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Scheme 2 Reagents and conditions: (i) 4-bromo-1-butene, NaI, MeOH, 
∆, 100%; (ii) TBDPSCl, imidazole, THF, rt, 86%; (iii) Boc2O, Et3N, 
DMAP, CH2Cl2, rt, 100%; (iv) TBAF, THF, 0 ºC, 100%; (v) (COCl)2, 
DMSO, Et3N, CH2Cl2, –78 °C, 94%; (vi) (EtO)2P(O)CH2CO2Et, DBU, 70 
LiCl, MeCN, rt, 94% from 9; (vii) DIBAL-H, BF3OEt2, CH2Cl2, –78 °C, 
41%; (viii) Ph3P=CHCHO, toluene, 80 °C, 75%; (ix) NaBH4, MeOH, 0 
°C, 88%. 
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Scheme 3 Reagents and conditions: (i) Cl3CCN, DBU (25 mol%), 
CH2Cl2, rt; (ii) PdCl2(MeCN)2 (10 mol%), CH2Cl2, rt; (iii) Grubbs II (10 
mol%), ∆, 79% over three steps. 
 
 Having developed the tandem process for the facile synthesis 90 
of 2,3,6,7-tetrahydro-3-amidoazepine 4, the programme of 
research then focused on the diasteroselective oxidation of this 
synthetic intermediate using the allylic trichloroacetamide moiety 
as a directing group. Initial studies focused on the preparation of 
the syn-diastereomer of the balanol core. Directed epoxidation of 95 
HN OH
OH
NH2
BocN
O
HN
CCl3
BocN
OH
4
56
H2N OH
H2N OH HN
OH
BocN
OTBDPS
i
ii, iii
iv
BocN
OH
v
vi
vii
BocN
OH
BocN CO2EtOBocN
BocN CHO
viii
ix
6
5
7
89
10 11
12
i
ii
iii
BocN
OH
BocN
O
HN
CCl3
BocN
O
HN
CCl3
BocN
O
HN
CCl3
5 13
144
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  3 
4 using m-CPBA18,19 gave 15 as a single diastereomer in 58% 
yield (Scheme 4). The relative stereochemistry was confirmed by 
difference NOE experiments which clearly showed the syn-
relationship of the 3-, 3a- and 4a-hydrogen atoms.20 
Regioselective reductive ring opening of the epoxide was 5 
performed using LiAlH4 which gave bicyclic oxazolidinone 16. 
Without purification, removal of the Boc-protecting group and 
hydrolysis of the oxazolidinone ring was achieved under acid 
mediated conditions to give the syn-diastereomer of the balanol 
core, (3S*,4R*)-3-aminoazepin-4-ol (17) in 61% yield from 15. 10 
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Scheme 4 Reagents and conditions: (i) m-CPBA, CH2Cl2, rt, 58%; (ii) 
LiAlH4, THF, ∆; (iii) 6N HCl, MeOH, rt, 61% over two steps. 
 In an effort to generate azepines with a higher level of 25 
substitution, conditions for the directed dihydroxylation of 4 were 
next investigated. Donohoe and co-workers have shown that 
highly stereoselective substrate directed dihydroxylation of cyclic 
allylic trichloroacetamides can be achieved using a reagent 
generated from osmium tetroxide and N,N,N’,N’-30 
tetramethylethylenediamine (TMEDA).21 This method proved 
particularly effective for the selective dihydroxylation of 
cycloheptenes.21c Using 2,3,6,7-tetrahydro-3-amidoazepine 4 as a 
substrate for this reaction gave syn-diol 18 in 81% yield and as a 
single diastereomer (Scheme 5). Difference NOE experiments 35 
confirmed the relative stereochemistry of 18 with clear 
correlation between the hydrogen atoms at C-3 and C-4.20 
Removal of the protecting groups under standard conditions gave 
(3S*,4S*,5R*)-3-aminoazepane-4,5-diol (19) in 78% yield. 
 Biologically active compounds incorporating an iodine atom 40 
are important both as synthetic intermediates in organic chemistry 
and as molecular tracers for single photon emission computed 
tomography (SPECT) imaging.22 It was proposed that 2,3,6,7-
tetrahydro-3-amidoazepine 4 could be used in a substrate directed 
iodination to access an iodinated stereoisomer of 17. Reaction of 45 
4 with N-iodosuccinimide gave 4,5-dihydro-1,3-oxazole 20 in 
78% yield (Scheme 5).23 As is well precedented for this 
reaction, generation of the iodonium intermediate takes place anti 
to the trichloroacetamide group.14e,23 This is followed by syn-
formation of the 4,5-dihydro-1,3-oxazole ring, ultimately yielding 50 
20 as a single diastereomer.20 Acid mediated hydrolysis of the 
4,5-dihydro-1,3-oxazole ring and concurrent removal of the Boc-
group was achieved under mild conditions to give (3S*,4S*,5S*)-
3-amino-5-iodoazepane-4-ol (21) in 77% yield. 
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Scheme 5 Reagents and conditions: (i) OsO4, TMEDA, CH2Cl2, –78 °C, 
81%; (ii) 2M NaOH, MeOH, 40 °C then 2M HCl, 78%; (iii) N-
iodosuccinimide, CHCl3, rt, 78%; (iv) 0.5M HCl, MeOH, rt, 77%. 
 While the oxidation of 2,3,6,7-tetrahydro-3-amidoazepine 4 
using these reactions leads to the highly efficient preparation of 70 
functionalised aminoazepanes as single diastereomers, these 
compounds are racemic due to the formation of 4 as a racemate 
during the three-step tandem process. We therefore wanted to 
demonstrate the enantioselective synthesis of 4. The groups of 
Richards and Overman have developed a series of chiral 75 
palladium(II) complexes such as (S)-COP-Cl 22 which have been 
shown to effect the rearrangement of allylic trichloroacetimidates 
in excellent yields and with high enantioselectivity.24 Using 
commercially available (S)-COP-Cl 22 (5 mol%) to catalyse the 
Overman rearrangement during the three-step tandem process 80 
gave (R)-2,3,6,7-tetrahydro-3-amidoazepine 4 in 92% yield and 
in 92% enantiomeric excess (Scheme 6).25 In a similar fashion, 
use of (R)-COP-Cl gave the (S)-enantiomer in 84% yield and in 
92% ee. Having demonstrated the asymmetric synthesis of 4, 
these products now have the potential to be used for the 85 
enantioselective preparation of highly functionalised 
aminoazepanes. 
 
Scheme 6 Reagents and conditions: (i) Cl3CCN, DBU, CH2Cl2, rt; (ii) 
(S)-COP-Cl (5 mol%), CH2Cl2, rt; (iii) Grubbs II (10 mol%), ∆, 92% over 90 
three steps; (iv) (R)-COP-Cl (5 mol%), CH2Cl2, rt; (v) Grubbs II (10 
mol%), ∆, 84% over three steps. 
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Conclusions 
In summary, a highly efficient, multi-bond forming, three-step 
tandem process has been developed for the racemic and 
asymmetric synthesis of a 2,3,6,7-tetrahydro-3-amidoazepine. 
The utility of this compound as a key intermediate for the 5 
diastereoselective preparation of a range of hydroxylated 
aminoazepanes was also demonstrated, including the synthesis of 
the syn-diastereomer of the balanol core. These studies have 
shown how the combination of an efficient multi-step tandem 
process followed by substrate directed reactions of the tetra-10 
hydroaminoazepine ring system can allow rapid access to highly 
functionalised azepane analogues. Work is currently underway to 
fully explore the asymmetric functionalisation of the chiral 
2,3,6,7-tetrahydro-3-amidoazepines for the preparation of more 
complex compounds with potential biological application. 15 
 
Experimental 
Reactions were performed in flame-dried glassware under a 
positive atmosphere of argon. All reagents and starting materials 
were obtained from commercial sources and used as received. 20 
Dry solvents were purified using a PureSolv 500 MD solvent 
purification system or tetrahydrofuran and diethyl ether were 
distilled from sodium and benzophenone, whilst dichloromethane 
was distilled from calcium hydride. Flash column 
chromatography was carried out using Fisher matrix silica 60. 25 
Macherey–Nagel aluminium-backed plates pre-coated with silica 
gel 60 (UV254) were used for thin layer chromatography and were 
visualised by staining with KMnO4. 1H NMR and 13C NMR 
spectra were recorded on a Bruker DPX 400 spectrometer with 
chemical shift values in ppm relative to TMS (δH 0.00 and δC 0.0) 30 
or residual chloroform (δH 7.28 and δC 77.2) as standard. 
Assignment of 1H and 13C NMR signals are based on two-
dimensional COSY and DEPT experiments, respectively. Mass 
spectra were obtained using a JEOL JMS-700 spectrometer. 
Infrared spectra were recorded using Golden Gate apparatus on a 35 
JASCO FTIR 410. Melting points were determined on a Reichert 
platform melting point apparatus. Optical rotations were 
determined as solutions irradiating with the sodium D line (λ = 
589 nm) using an Auto pol V polarimeter. [α]D values are given 
in units 10–1 deg cm2 g–1. The chiral HPLC methods were 40 
calibrated with their corresponding racemic mixtures. (S)-COP-Cl 
22 refers to di-µ-chlorobis[η5-(S)-(ρR)-2-(2’-(4’-
methylethyl)oxazolinyl)cyclopentadienyl, 1-C, 3’-N)(η4-
tetraphenylcyclobutadiene)cobalt]dipalladium and (R)-COP-Cl 
refers to di-µ-chlorobis[η5-(R)-(ρR)-2-(2’-(4’-45 
methylethyl)oxazolinyl)cyclopentadienyl, 1-C, 3’-N)(η4-
tetraphenylcyclobutadiene)cobalt]dipalladium. 
 
N-[2′-(tert-Butyldiphenylsilyloxy)ethyl]-1-aminobut-3-ene 
Sodium iodide (0.55 g, 3.70 mmol) was added to a solution of 4-50 
bromo-1-butene (5.00 g, 37.1 mmol) and 2-aminoethanol (6) 
(8.85 mL, 185.3 mmol) in methanol (80 mL). The reaction 
mixture was heated under reflux for 2 h, then cooled to room 
temperature and evaporated in vacuo. The residue was partitioned 
between saturated aqueous ammonium chloride solution (20 mL) 55 
and ethyl acetate (20 mL). The aqueous layer was made basic 
with 40% sodium hydroxide and extracted with ethyl acetate (3 × 
15 mL). The combined organic layers were dried (MgSO4) and 
concentrated to afford N-[2′-(hydroxy)ethyl]-1-aminobut-3-ene 
(7) (4.26 g, 100% yield) as a colourless oil. This oil was 60 
dissolved in tetrahydrofuran (200 mL) and tert-butyldiphenylsilyl 
chloride (14.44 mL, 55.6 mmol) and imidazole (5.04 g, 74.1 
mmol) were added. The reaction mixture was stirred overnight at 
room temperature. A white precipitate was removed by filtration 
and washed with diethyl ether (70 mL). The combined filtrate 65 
was concentrated, dried (MgSO4) and purified by flash column 
chromatography on silica gel (elution with dichloromethane/ethyl 
acetate, 1:5) to give N-[2′-(tert-butyldimethylsilyloxy)ethyl]-1-
aminobut-3-ene (9.43 g, 86%) as a colourless oil. υmax/cm–1 (neat) 
3071 (NH), 2932 (CH), 1465, 1080, 910, 702; δH (400 MHz, 70 
CDCl3) 1.08 (9H, s, SiC(CH3)3), 2.31 (2H, qt, J 6.8, 0.8 Hz, 2-
H2), 2.72 (2H, t, J 6.8 Hz, 1-H2), 2.79 (2H, t, J 5.4 Hz, 1′-H2), 
3.81 (2H, t, J 5.4 Hz, 2′-H2), 5.06–5.18 (2H, m, 4-H2), 5.17 (1H, 
ddt, J 17.1, 10.2, 6.8 Hz, 3-H), 7.38–7.49 (6H, m, ArH), 7.68–
7.72 (4H, m, ArH); δC (101 MHz, CDCl3) 19.2 (C), 26.9 (3 × 75 
CH3), 34.4 (CH2), 48.6 (CH2), 51.5 (CH2), 63.1 (CH2), 116.4 
(CH2), 127.7 (4 × CH), 129.7 (2 × CH), 133.7 (2 × C), 135.6 (4 × 
CH), 136.5 (CH); m/z (CI) 354.2254 (MH+. C22H32NOSi requires 
354.2253), 312 (6%), 257 (8), 193 (5), 137 (7), 113 (28), 85 (89), 
69 (100). 80 
 
N-2′-(tert-Butyldiphenylsilyloxy)ethyl-N-(tert-
butoxycarbonyl)-1-aminobut-3-ene (8) 
To a solution of N-[2′-(tert-butyldimethylsilyloxy)ethyl]-1-
aminobut-3-ene (4.00 g, 11.3 mmol) in dichloromethane (100 85 
mL) at 0 °C was added triethylamine (3.31 mL, 23.7 mmol), 4-
dimethylaminopyridine (0.14 g, 1.30 mmol) and di-tert-butyl 
dicarbonate (4.93 g, 22.6 mmol). The reaction mixture was 
warmed to room temperature and stirred overnight. The reaction 
mixture was washed with brine (2 × 30 mL), dried (MgSO4) and 90 
concentrated in vacuo. Purification by flash column 
chromatography (elution with ethyl acetate/diethyl ether, 1:10) 
gave N-2′-(tert-butyldiphenylsilyloxy)ethyl-N-(tert-
butoxycarbonyl)-1-aminobut-3-ene (8) (5.1 g, 100%) as a 
colourless oil. υmax/cm–1 (neat) 2932 (CH), 1690 (CO), 1474, 95 
1412, 1265, 1157, 1111, 825; NMR spectra showed a 1:1 mixture 
of rotomers, only signals for one rotomer is recorded: δH (400 
MHz, CDCl3) 1.05 (9H, s, SiC(CH3)3), 1.37 (9H, s, OC(CH3)3), 
2.20–2.29 (2H, m, 2-H2), 3.25–3.40 (4H, m, 1-H2 and 1′-H2), 
3.25–3.39 (2H, m, 2′-H2), 4.96–5.06 (2H, m, 4-H2), 5.66–5.81 100 
(1H, m, 3-H), 7.33–7.44 (6H, m, ArH), 7.63–7.67 (4H, m, ArH); 
δC (101 MHz, CDCl3) 19.2 (C), 26.9 (3 × CH3), 28.5 (3 × CH3), 
32.7 (CH2), 45.6 (CH2), 49.5 (CH2), 62.5 (CH2), 83.0 (C), 116.4 
(CH2), 127.7 (4 × CH), 129.7 (2 × CH), 133.6 (2 × C), 135.3 (4 × 
CH), 135.8 (CH), 155.4 (C); m/z (CI) 454.2772 (MH+. 105 
C27H40NO3Si requires 454.2777), 398 (18%), 354 (28), 340 (12), 
320 (8), 257 (8), 179 (5), 139 (6), 97 (28), 85 (87), 69 (100). 
 
N-2′-(Hydroxy)ethyl-N-(tert-butoxycarbonyl)-1-aminobut-3-
ene (9) 110 
A solution of n-tetrabutylammonium fluoride (1.0 M in 
tetrahydrofuran) (13.6 mL, 13.6 mmol) was added to a solution of 
N-2′-(tert-butyldiphenylsilyloxy)ethyl-N-(tert-butoxycarbonyl)-1-
aminobut-3-ene (8) (5.12 g, 11.3 mmol) in tetrahydrofuran (100 
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mL) at 0 °C. The reaction mixture was warmed to room 
temperature and stirred overnight. The reaction mixture was then 
concentrated and the resulting residue was re-suspended in 
diethyl ether (80 mL). The solution was washed with water (40 
mL) and the aqueous layer was then extracted with diethyl ether 5 
(3 × 40 mL). The combined organic extracts were dried (MgSO4), 
concentrated and then purified by flash column chromatography 
(petroleum ether/diethyl ether, 1:5) to give N-2′-(hydroxy)ethyl-
N-(tert-butoxycarbonyl)-1-aminobut-3-ene (9) (2.42 g, 100%) as 
a colourless oil. υmax/cm–1 (neat) 3742 (OH), 2978 (CH), 1690 10 
(CO), 1474, 1412, 1250, 1157, 910, 733; δH (400 MHz, CDCl3) 
1.48 (9H, s, OC(CH3)3), 2.30 (2H, q, J 6.8 Hz, 2-H2), 3.25–3.35 
(2H, m, 1-H2), 3.40 (2H, t, J 4.8 Hz, 1′-H2), 3.80 (2H, t, J 4.8 Hz, 
2′-H2), 5.03–5.12 (2H, m, 4-H2), 5.71–5.84 (1H, m, 3-H); δC (101 
MHz, CDCl3) 28.4 (3 × CH3), 33.3 (CH2), 48.5 (CH2), 50.6 15 
(CH2), 62.8 (CH2), 80.2 (C), 116.8 (CH2), 135.3 (CH), 155.5 (C); 
m/z (CI) 216.1603 (MH+. C11H22NO3 requires 216.1600), 202 
(5%), 174 (8), 160 (100), 116 (6), 85 (21), 69 (28). 
 
Ethyl (2′E)-N-(butyl-3-en-1-yl)-N-(tert-butoxycarbonyl)-1′-20 
aminobut-2′-enoate (11) 
Dimethyl sulfoxide (2.36 mL, 33.2 mmol) was added to a stirred 
solution of oxalyl chloride (1.58 mL, 18.6 mmol) in 
dichloromethane (50 mL) at –78 °C. The reaction mixture was 
stirred for 0.3 h before N-2′-(hydroxy)ethyl-N-(tert-25 
butoxycarbonyl)-1-aminobut-3-ene (9) (2.86 g, 13.3 mmol) in 
dichloromethane (50 mL) was slowly added. The mixture was 
stirred for a further 0.3 h before triethylamine (9.27 mL, 66.5 
mmol) was added. This reaction mixture was stirred for 0.5 h at –
78 °C and then allowed to warm to room temperature and stirred 30 
for a further 2 h. Meanwhile, a solution of lithium chloride (1.01 
g, 23.9 mmol), triethyl phosphonoacetate (4.75 mL, 23.9 mmol) 
and 1,8-diazabicyclo[5,4,0]undec-7-ene (3.58 mL, 23.9 mmol) in 
acetonitrile (100 mL) was prepared and stirred for 1.0 h. The 
Swern solution was concentrated in vacuo, then the Horner-35 
Wadsworth-Emmons solution was added and the reaction mixture 
was stirred at room temperature overnight. The reaction was 
quenched by the addition of a saturated solution of ammonium 
chloride (50 mL) and concentrated to give an orange residue, 
which was then extracted with diethyl ether (4 × 75 mL). The 40 
organic layers were combined, dried (MgSO4) and concentrated 
to give an orange oil. Purification by flash column 
chromatography (diethyl ether/petroleum ether, 2:3) gave ethyl 
(2′E)-N-(butyl-3-en-1-yl)-N-(tert-butoxycarbonyl)-1′-aminobut-
2′-enoate (11) (2.90 g, 94%) as colourless oil. υmax/cm–1 (NaCl) 45 
2978 (CH), 1690 (CO), 1466, 1412, 1366, 1273, 1165, 910, 725; 
NMR spectra showed a 1:1 mixture of rotomers, only signals for 
one rotomer is recorded: δH (400 MHz, CDCl3) 1.32 (3H, t, J 7.3 
Hz, OCH2CH3), 1.49 (9H, s, OC(CH3)3), 2.25–2.35 (2H, m, 2-
H2), 3.19–3.36 (2H, m, 1-H2), 3.93–4.06 (2H, m, 1′-H2), 4.23 50 
(2H, q, J 7.3 Hz, OCH2CH3), 5.02–5.14 (2H, m, 4-H2), 5.71–5.80 
(1H, m, 3-H), 5.88 (1H, dt, J 15.6, 1.8 Hz, 3′-H), 6.89 (1H, dt, J 
15.6, 4.7 Hz, 2′-H); δC (101 MHz, CDCl3) 14.2 (CH3), 28.4 (3 × 
CH3), 33.1 (CH2), 46.8 (CH2), 47.8 (CH2), 60.5 (CH2), 80.0 (C), 
116.9 (CH2), 121.8 (CH), 135.2 (CH), 144.2 (CH), 155.3 (C), 55 
166.1 (C); m/z (CI) 284.1862 (MH+. C15H26NO4 requires 
284.1862), 228 (94%), 184 (62), 142 (10) 113 (32), 97 (35), 85 
(82), 71 (100). 
 
(2E)-N-(Butyl-3-en-1-yl)-N-(tert-butoxycarbonyl)-1′-60 
aminobut-2′-en-4′-ol (5) 
A stirred solution of (2′E)-N-(butyl-3-en-1-yl)-N-(tert-
butoxycarbonyl)-1′-aminobut-2′-enoate (11) (0.25 g, 0.90 mmol) 
in dichloromethane (30 mL) was cooled to –78 °C before boron 
trifluoride diethyl etherate (0.15 mL, 1.17 mmol) was added 65 
dropwise. The mixture was stirred at –78 °C for 0.5 h before 
diisobutylaluminium hydride solution (1.0 M in hexanes, 2.7 mL, 
2.7 mmol) was added dropwise. The reaction mixture was then 
stirred at –78 °C for 3 h before being quenched by the addition of 
5.0 M acetic acid solution in dichloromethane (10 mL). The 70 
mixture was poured into 10% aqueous tartaric acid solution (10 
mL), and the organic layers were extracted using 
dichloromethane (2 × 20 mL). The combined organic layers were 
washed with a saturated aqueous solution of sodium hydrogen 
carbonate (15 mL) before being dried (MgSO4), filtered, and 75 
concentrated in vacuo. The crude product was purified by flash 
column chromatography (petroleum ether/diethyl ether, 2:5) to 
give (2E)-N-(butyl-3-en-1-yl)-N-(tert-butoxycarbonyl)-1′-
aminobut-2′-en-4′-ol (5) (0.09 g 41%) as a colourless oil. 
υmax/cm–1 (neat) 3433 (OH), 2978 (CH), 1674 (CO), 1474, 1412, 80 
1366, 1242, 1165, 918; δH (400 MHz, CDCl3) 1.38 (9H, s, 
OC(CH3)3), 2.18 (2H, q, J 7.5 Hz, 2-H2), 3.06–3.22 (2H, m, 1-
H2), 3.66–3.79 (2H, m, 1′-H2), 4.13 (2H, d, J 4.1 Hz, 4′-H2), 
4.89–5.02 (2H, m, 4-H2), 5.49–5.76 (3H, m, 3-H, 2′-H and 3′-H); 
δC (101 MHz, CDCl3) 28.5 (3 × CH3), 32.5 (CH2), 46.3 (CH2), 85 
48.3 (CH2), 63.1 (CH2), 79.5 (C), 116.5 (CH2), 127.9 (CH), 131.0 
(CH), 135.5 (CH), 155.4 (C); m/z (CI) 242.1752 (MH+. 
C13H24NO3 requires 242.1756), 224 (8%), 200 (9), 186 (100), 168 
(72), 160 (12), 113 (14), 85 (28), 73 (38).  
 90 
N-(2′-Oxoethyl)-N-(tert-butoxycarbonyl)-1-aminobut-3-ene 
(10) 
Dimethyl sulfoxide (4.20 mL, 59.2 mmol) was added to a stirred 
solution of oxalyl chloride (3.10 mL, 35.5 mmol) in 
dichloromethane (50 mL) at –78 °C. The reaction mixture was 95 
stirred for 0.3 h before N-2′-(hydroxy)ethyl-N-(tert-
butoxycarbonyl)-1-aminobut-3-ene (9) (5.10 g, 23.7 mmol) in 
dichloromethane (25 mL) was slowly added. The mixture was 
stirred for a further 0.3 h before triethylamine (16.5 mL, 118.4 
mmol) was added. This reaction mixture was stirred for 0.5 h at –100 
78 °C and then allowed to warm to room temperature and stirred 
for a further 2 h. The reaction mixture was concentrated in vacuo, 
and purified by flash column chromatography (petroleum 
ether/diethyl ether, 2:5) to give N-(2′-oxoethyl)-N-(tert-
butoxycarbonyl)-1-aminobut-3-ene (10) (4.74 g, 94%) as a 105 
colourless oil. υmax/cm–1 (neat) 2982 (CH), 1736 (CO), 1686 
(CO), 1424, 1370, 1216, 1153, 907, 729; NMR spectra showed a 
1:1 mixture of rotomers, only signals for one rotomer is recorded: 
δH (400 MHz, CDCl3) 1.45 (9H, s, OC(CH3)3), 2.23–2.33 (2H, m, 
2-H2), 3.30 (2H, t, J 7.1 Hz, 1-H2), 3.80 (2H, br s, 1′-H2), 5.02–110 
5.11 (2H, m, 4-H2), 5.68–5.83 (1H, m, 3-H), 9.56 (1H, br s, 2’-
H); δC (101 MHz, CDCl3) 28.2 (3 × CH3), 33.0 (CH2), 48.5 
(CH2), 57.7 (CH2), 80.8 (C), 117.2 (CH2), 135.1 (CH), 155.0 (C), 
199.4 (C); m/z (CI) 214.1440 (MH+. C11H20NO3 requires 
214.1443), 200 (10%), 196 (8), 158 (100), 114 (9), 85 (7), 69 115 
(12). 
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(2′E)-N-(Butyl-3-en-1-yl)-N-(tert-butoxycarbonyl)-1′-
aminobut-2′-en-4′-al (12). 
To a solution of N-(2′-oxoethyl)-N-(tert-butoxycarbonyl)-1-
aminobut-3-ene (10) (1.60 g, 7.51 mmol) in toluene (80 mL) was 5 
added (triphenylphosphoranylidene)acetaldehyde (3.42 g, 11.3 
mmol) and the reaction mixture was heated at 80 °C and stirred 
for 24 h. The solution was allowed to cool to room temperature 
and concentrated in vacuo. The resulting residue was purified 
with flash column chromatography (petroleum ether/diethyl 10 
ether, 2:5) to give (2′E)-N-(butyl-3-en-1-yl)-N-(tert-
butoxycarbonyl)-1′-aminobut-2′-en-4′-al (12) (1.35 g, 75%) as 
colourless oil. υmax/cm–1 (neat) 2982 (CH), 2361, 1678 (CO), 
1416, 1215, 1169, 918, 745; NMR spectra showed a 1:1 mixture 
of rotomers, only signals for one rotomer is recorded: δH (400 15 
MHz, CDCl3) 1.51 (9H, s, OC(CH3)3), 2.26–2.36 (2H, m, 2-H2), 
3.22–3.38 (2H, m, 1-H2), 4.05–4.19 (2H, m, 1′-H2), 5.05–5.15 
(2H, m, 4-H2), 5.71–5.85 (1H, m, 3-H), 6.17 (1H, ddt, J 15.8, 7.9, 
1.6 Hz, 3′-H), 6.72–6.86 (1H, m, 2′-H), 9.62 (1H, d, J 7.9 Hz, 4’-
H); δC (101 MHz, CDCl3) 28.4 (3 × CH3), 33.2 (CH2), 47.2 20 
(CH2), 48.3 (CH2), 80.3 (C), 117.0 (CH2), 125.3 (CH), 129.1 
(CH), 132.3 (CH), 153.4 (C), 193.2 (C); m/z (CI) 240.1595 (MH+. 
C13H22NO3 requires 240.1600), 236 (19%), 210 (96), 184 (100), 
158 (40), 116 (58), 69 (12). 
 25 
(2E)-N-(Butyl-3-en-1-yl)-N-(tert-butoxycarbonyl)-1′-
aminobut-2′-en-4′-ol (5) 
To a solution of (2′E)-N-(butyl-3-en-1-yl)-N-(tert-
butoxycarbonyl)-1′-aminobut-2′-en-4′-al (12) (0.30 g, 1.28 mmol) 
in methanol (35 mL) at 0 °C was added sodium borohydride (0.09 30 
g, 2.56 mmol). After 1 h, the reaction mixture was quenched with 
1.0 M hydrochloric acid (5 mL) and then concentrated in vacuo. 
The residue was dissolved in dichloromethane (20 mL), washed 
with saturated sodium hydrogencarbonate solution (10 mL), dried 
(MgSO4), and concentrated in vacuo. The crude product was 35 
purified by flash column chromatography (petroleum 
ether/diethyl ether, 2:5) to give (2E)-N-(butyl-3-en-1-yl)-N-(tert-
butoxycarbonyl)-1′-aminobut-2′-en-4′-ol (5) (0.26 g 88%) as a 
colourless oil. Spectroscopic data as reported above. 
 40 
1-(tert-Butoxycarbonyl)-2,3,6,7-tetrahydro-3-(2′,2′,2′-
trichloromethylcarbonylamino)azepine (4) 
(2E)-N-(Butyl-3-en-1-yl)-N-(tert-butoxycarbonyl)-1′-aminobut-
2′-en-4′-ol (5) (0.13 g, 0.54 mmol) was dissolved in 
dichloromethane (20 mL) and cooled to 0 °C. 1,8-45 
Diazabicyclo[5.4.0]undec-7-ene (0.02 mL, 0.14 mmol) was 
added to the solution followed by trichloroacetonitrile (0.08 mL, 
0.81 mmol). The reaction mixture was then warmed to room 
temperature and stirred for 2 h. The reaction mixture was filtered 
through a short pad of silica gel and washed with diethyl ether 50 
(100 mL). The resulting filtrate was then concentrated to give 
allylic trichloroacetimidate 13, which was used without further 
purification. Allylic trichloroacetimidate 13 was then dissolved in 
dichloromethane (10 mL). Bis(acetonitrile)palladium(II) chloride 
(0.014 g, 0.05 mmol)  was added to the solution and the reaction 55 
mixture was stirred at room temperature for 3 h. Grubbs first 
generation catalyst (0.044 g, 0.05 mmol) was then added and the 
reaction mixture was heated under reflux for 96 h. The reaction 
mixture was cooled to room temperature and then filtered through 
a short pad of Celite and washed with diethyl ether (100 mL). 60 
Concentration of the filtrate, followed by flash column 
chromatography (petroleum ether/diethylether, 2:1) gave 1-(tert-
butoxycarbonyl)-2,3,6,7-tetrahydro-3-(2′,2′,2′-
trichloromethylcarbonylamino)azepine (4) (0.09 g, 49% over 
three steps) as a white solid. Mp 103–105 °C; υmax/cm–1 (NaCl) 65 
3330 (NH), 2978 (CH), 1690 (CO), 1419, 1366, 1165, 756; NMR 
spectra showed a 1:1 mixture of rotomers, only signals for one 
rotomer is recorded: δH (400 MHz, CDCl3) 1.47 (9H, s, 
OC(CH3)3), 2.17–2.42 (2H, m, 6-H2), 3.03–3.16 (1H, m, 7-HH), 
3.32 (1H, dd, J 14.9, 2.6 Hz, 2-HH), 3.72–3.81 (1H, m, 7-HH), 70 
4.05 (1H, br d, J 14.9 Hz, 2-HH), 4.43–4.59 (1H, m, 3-H), 5.53–
5.93 (2H, m, 4-H and 5-H), 8.30 (1H, br s, NH); δC (101 MHz, 
CDCl3) 27.9 (CH2), 28.4 (3 × CH3), 47.7 (CH2), 48.7 (CH2), 54.2 
(CH), 80.7 (C), 92.1 (C), 128.6 (CH), 129.5 (CH), 157.2 (C), 
163.7 (C); m/z (CI) 359.0511 (MH+. C13H2035Cl237ClN2O3 75 
requires 359.0512), 301 (100%), 267 (34), 257 (18), 223 (7), 163 
(8), 85 (13), 69 (19). 
 
1-(tert-Butoxycarbonyl)-2,3,6,7-tetrahydro-3-(2′,2′,2′-
trichloromethylcarbonylamino)azepine (4) 80 
The reaction was carried out as described above except using 
(2E)-N-(butyl-3-en-1-yl)-N-(tert-butoxycarbonyl)-1′-aminobut-2′-
en-4′-ol (5) (0.13 g, 0.54 mmol) and Grubbs second generation 
catalyst (0.044 g, 0.05 mmol) for the RCM step which was 
complete in 12 h. Purification by flash column chromatography 85 
(petroleum ether/diethylether, 2:1) gave 1-(tert-butoxycarbonyl)-
2,3,6,7-tetrahydro-3-(2′,2′,2′-
trichloromethylcarbonylamino)azepine (4) (0.15 g, 79% over 
three steps) as a white solid. Spectroscopic data as reported 
above. 90 
 
2′,2′,2′-Trichloro-N-[(3S*,3aS*,4aR*)-1-tert-
butoxycarbonylamino-4-oxobicyclo[5.1.0]octa-3a-
yl]acetamide (15) 
1-(tert-Butoxycarbonyl)-2,3,6,7-tetrahydro-3-(2′,2′,2′-95 
trichloromethylcarbonylamino)azepine (4) (0.19 g, 0.53 mmol) 
was dissolved in dichloromethane (15 mL) and to the stirred 
suspension was added meta-chloroperoxybenzoic acid (0.18 g 
1.05 mmol) at room temperature. The resulting suspension was 
stirred vigorously for 19 h. A 20% aqueous solution of sodium 100 
sulfite (10 mL) was added and the resulting two-phase mixture 
was stirred vigorously for 0.25 h. The two layers were separated 
and the aqueous layer was extracted with dichloromethane (2 × 
20 mL). The combined organic layers were washed with a 20% 
aqueous solution of sodium sulfite (10 mL) and a 5% aqueous 105 
solution of sodium hydrogencarbonate (2 × 20 mL), dried 
(MgSO4) and evaporated under reduced pressure. Purification by 
flash column chromatography (elution with petroleum 
ether/diethyl ether, 2:5) gave 2′,2′,2′-trichloro-N-
[(3S*,3aS*,4aR*)-1-tert-butoxycarbonylamino-4-110 
oxobicyclo[5.1.0]octa-3a-yl]acetamide (15) (0.11 g, 58%) as 
white solid. Mp 160–162 °C; υmax/cm–1 (NaCl) 3293 (NH), 2974 
(CH), 1697 (CO), 1518, 1414, 1368, 1165, 943, 821; NMR 
spectra showed a 2:1 mixture of rotomers, only signals for major 
rotomer is recorded: δH (400 MHz, CDCl3) 1.50 (9H, s, 115 
OC(CH3)3), 2.21–2.37 (2H, m, 5-H2), 2.78–2.93 (1H, m, 2-H2), 
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3.26–3.33 (2H, m, 6-H2), 3.83 (1H, dd, J 13.6, 4.4 Hz, 3a-H), 
3.86–3.93 (1H, m, 4a-H), 4.59 (1H, td, J 9.2, 4.4 Hz, 3-H), 6.90 
(1H, br d, J 9.2 Hz, NH); δC (101 MHz, CDCl3) 27.6 (CH2), 28.4 
(3 × CH3), 43.2 (CH2), 46.5 (CH2), 50.7 (CH), 55.4 (CH), 58.7 
(CH), 80.7 (C), 92.3 (C), 154.3 (C), 161.4 (C); m/z (CI) 375.0453 5 
(MH+. C13H2035Cl237ClN2O4 requires 375.0461), 319 (100%), 283 
(76), 273 (10), 239 (8), 211 (8), 155 (10), 81 (6), 69 (11). 
 
(3S*,4R*)-3-Aminoazepin-4-ol (17)8h 
2′,2′,2′-Trichloro-N-[(3S*,3aS*,4aR*)-1-tert-10 
butoxycarbonylamino-4-oxobicyclo[5.1.0]octa-3a-yl]acetamide 
(15) (0.05 g, 0.14 mmol) was dissolved in tetrahydrofuran (10 
mL) and cooled to 0 °C. Lithium aluminium hydride (0.03 g, 0.71 
mmol) was then added and the slurry was heated under reflux for 
12 h. The solution was cooled to room temperature and 15 
concentrated in vacuo. The crude material was dissolved in 
methanol (2 mL) and 6.0 N hydrochloric acid (2 mL) was added. 
The reaction mixture was stirred at room temperature for 12 h 
and then concentrated in vacuo. Purification by ion exchange 
column chromatography (Dowex® 50WX8-100), eluting with 0.5 20 
M ammonia solution gave (3S*,4R*)-3-aminoazepin-4-ol (17) 
(0.01 g 61% over two steps) as a viscous oil. Spectroscopic data 
as previously reported.8h υmax/cm–1 (neat) 3369 (NH/OH), 2922 
(CH), 1637, 1544, 1463, 1016; δH (500 MHz, CDCl3) 1.86–1.96 
(2H, m, 6-H2), 2.17–2.25 (1H, m, 5-HH), 2.42–2.48 (1H, m, 2-25 
HH), 2.57 (1H, td, J 10.0, 1.8 Hz, 7-HH), 2.76–2.86 (2H, m, 2-
HH and 5-HH), 3.09–3.14 (2H, m, 4-H and 7-HH), 3.17–3.21 
(1H, m, 3-H); δC (126 MHz, CDCl3) 29.7 (CH2), 31.7 (CH2), 45.3 
(CH2), 54.3 (CH), 54.5 (CH2), 62.3 (CH); m/z (CI) 131 (MH+, 
4%), 121 (100), 117 (70), 113 (15), 85 (18), 61 (19). 30 
 
(3S*,4S*,5R*)-1-(tert-Butoxycarbonyl)-3-(2′,2′,2′-
trichloromethylcarbonylamino)-4,5-dihydroxyazepane (18) 
1-(tert-Butoxycarbonyl)-2,3,6,7-tetrahydro-3-(2′,2′,2′-
trichloromethylcarbonylamino)azepine (4)  (0.048 g, 0.134 35 
mmol) was dissolved in dichloromethane (8 mL) at –78 °C. 
Tetramethylethylenediamine (0.024 mL, 0.147 mmol) was added 
and the reaction mixture stirred for 0.1 h before the addition of 
osmium tetroxide (0.04 g, 0.157 mmol). The dark coloured 
solution was stirred for 1 h at –78 °C before warming to room 40 
temperature. The reaction mixture was stirred for a further 1 h. 
The solvent was removed in vacuo and the dark coloured solid 
was dissolved in 1:1 mixture of tetrahydrofuran and a saturated 
solution of aqueous sodium sulfite (10 mL). The reaction mixture 
was stirred and heated under reflux for 12 h. The solvent was 45 
removed in vacuo to afford a dark solid. Flash column 
chromatography (elution with ethyl acetate) afforded 
(3S*,4S*,5R*)-1-(tert-butoxycarbonyl)-3-(2′,2′,2′-trichloromethyl 
carbonylamino)-4,5-dihydroxyazepane (18) (0.042 g, 81%) as a 
white solid. Mp 153–155 °C; υmax/cm–1 (NaCl) 3390 (NH/OH), 50 
2967 (CH), 1672 (CO), 1471, 1249, 956; NMR spectra showed a 
1:1 mixture of rotomers, only signals for one rotomer is recorded: 
δH (400 MHz, CDCl3) 1.45 (9H, s, OC(CH3)3), 1.64–1.75 (1H, m, 
6-HH), 2.06–2.17 (1H, m, 6-HH), 2.77 (1H, br s, OH), 3.25–3.92 
(4H, m, 4-H, 5-H and 7-H2), 4.11–4.31 (2H, m, 2-H2), 4.67–4.79 55 
(1H, m, 3-H), 5.37 (1H, br s, NH); δC (126 MHz, CDCl3) 28.4 (3 
× CH3), 29.7 (CH2), 31.6 (CH2), 47.6 (CH2), 53.1 (CH), 70.1 
(CH), 77.3 (CH), 80.6 (C), 92.3 (C), 155.4 (C), 158.4 (C); m/z 
(EI) 390.0523 (M+. C13H2135Cl3N2O5 requires 390.0516), 354 
(11%), 339 (20), 283 (8), 216 (28), 191 (100), 172 (9), 111 (18), 60 
83 (35), 57 (98). 
 
(3S*,4S*,5R*)-3-Aminoazepane-4,5-diol (19) 
To a solution of (3S*,4S*,5R*)-1-(tert-butoxycarbonyl)-3-
(2′,2′,2′-trichloromethylcarbonylamino)-4,5-dihydroxyazepane 65 
(18) (0.023 g, 0.051 mmol) in methanol (5 mL) was added 2.0 M 
sodium hydroxide (3 mL) and the reaction mixture was stirred at 
40 °C for 12 h. 2.0 M Hydrochloric acid (10 mL) was added and 
the reaction was stirred for 1 h. The reaction mixture was 
concentrated in vacuo. The resulting residue was dissolved in 70 
chloroform (20 mL) and washed with water (10 mL). The organic 
layer was dried (MgSO4) and concentrated under vacuum to give 
(3S*,4S*,5R*)-3-aminoazepane-4,5-diol (19) as a white solid 
(0.07 g, 78%). Mp 172–174 °C (decomposition); υmax/cm–1 
(NaCl) 3379 (NH/OH), 2931 (CH), 1649, 1448, 1211, 970; δH 75 
(500 MHz, D2O) 2.33–2.41 (1H, m, 6-HH), 2.49–2.61 (1H, m, 6-
HH), 3.51–3.60 (1H, m, 7-HH), 3.80–3.88 (2H, m, 2-HH and 7-
HH), 3.96–4.04 (1H, m, 3-H), 4.29–4.40 (2H, m, 2-HH and 5-H), 
4.59–4.65 (1H, m, 4-H); δC (126 MHz, CD3OD) 28.4 (CH2), 43.4 
(CH2), 43.6 (CH2), 50.0 (CH), 72.0 (CH), 73.0 (CH); m/z (CI) 80 
147.1140 (MH+. C6H15N2O2 requires 147.1133), 127 (100), 113 
(4), 101 (12), 81 (8), 69 (11). 
 
(3aS*,8S*,8aS*)-1-Oxo-2-trichloromethyl-3,5-diaza-5-(tert-
butoxycarbonyl)-8-iodo-1,3a,4,5,6,7,8,8a-octahydroazulene 85 
(20) 
To a solution of 1-(tert-butoxycarbonyl)-3-(2′,2′,2′-
trichloromethylamino)azapin-4-ene (4) (0.05 g, 0.139 mmol) in 
chloroform (8 mL), N-iodosuccinimide (0.05 g, 0.230 mmol) was 
added and the mixture stirred for 18 h. The solvent was then 90 
removed in vacuo. The resulting residue was dissolved in ethyl 
acetate (20 mL) and the organic layer washed with water (4 × 30 
mL). The organic layer was then dried (MgSO4) and the solvent 
removed in vacuo. Purification by flash column chromatography 
(elution with petroleum ether/diethyl ether, 5:1) gave 95 
(3aS*,8S*,8aS*)-1-oxo-2-trichloromethyl-3,5-diaza-5-(tert-
butoxycarbonyl)-8-iodo-1,3a,4,5,6,7,8,8a-octahydroazulene (20) 
(0.052 g, 78%) as a white solid. Mp 130–133 °C; υmax/cm–1 
(NaCl) 2933 (CH), 1684 (CO), 1417, 1243, 1164, 754; δH (500 
MHz, CDCl3) 1.47 (9H, s, OC(CH3)3), 1.98–2.15 (1H, m, 7-HH), 100 
2.25–2.39 (1H, m, 7-HH), 3.31–4.03 (4H, m, 6-H2 and 4-H2), 
4.51–4.62 (1H, m, 8-H), 4.63–4.75 (1H, m, 3a-H), 5.26 (1H, t, J 
8.2 Hz, 8a-H); δC (126 MHz, CDCl3) 26.3 (CH2), 28.4 (3 × CH3), 
29.9 (CH2), 36.2 (CH), 48.1 (CH2), 68.9 (CH), 80.6 (CH), 86.2 
(C), 89.6 (C), 154.7 (C), 161.0 (C); m/z (CI) 482.9496 (MH+. 105 
C13H1935Cl3IN2O3 requires 482.9506), 427 (38%), 393 (8), 301 
(6), 199 (4), 164 (13), 100 (100). 
 
(3S*,4S*,5S*)-3-Amino-5-iodoazepane-4-ol (21) 
To a solution of (3aS*,8S*,8aS*)-1-oxo-2-trichloromethyl-3,5-110 
diaza-5-(tert-butoxycarbonyl)-8-iodo-1,3a,4,5,6,7,8,8a-
octahydroazulene (20) (0.047 g, 0.097 mmol) in methanol (5 mL) 
was added 0.5 M hydrochloric acid (5 mL) and the reaction 
mixture was stirred at room temperature for 0.5 h. The reaction 
mixture was then diluted with a saturated solution of sodium 115 
hydrogencarbonate (10 mL) and extracted with ethyl acetate (3 × 
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20 mL). The organic layers were combined, dried (MgSO4) and 
concentrated in vacuo to give (3S*,4S*,5S*)-3-amino-5-
iodoazepane-4-ol (21) (0.03 g, 77%) as a white solid. Mp 154–
155 °C; υmax/cm–1 (NaCl) 3450 (OH), 3337 (NH), 2957 (CH), 
1665, 1463, 1272, 741; δH (500 MHz, CD3OD) 2.21–2.29 (1H, m, 5 
6-HH), 2.55–2.62 (1H, m, 6-HH), 3.36 (1H, dd, J 13.5, 3.2 Hz, 2-
HH), 3.41–3.49 (2H, m, 7-H2), 3.72 (1H, dd J 13.5, 10.0 Hz, 2-
HH), 4.24 (1H, dt, J 10.0, 3.2 Hz, 3-H), 4.42–4.45 (1H, m, 4-H), 
4.61 (1H, dt, J 6.1, 3.5 Hz, 5-H); δC (126 MHz, CD3OD) 29.2 
(CH2), 30.7 (CH), 41.5 (CH2), 45.9 (CH2), 49.8 (CH), 74.8 (CH); 10 
m/z (CI) 257.0158 (MH+. C6H14IN2O requires 257.0151), 217 
(20), 173 (12), 146 (8), 113 (8), 73 (22). 
 
(3R)-1-(tert-Butoxycarbonyl)-2,3,6,7-tetrahydro-3-(2′,2′,2′-
trichloromethylcarbonylamino)azepine 15 
(2E)-N-(Butyl-3-en-1-yl)-N-(tert-butoxycarbonyl)-1′-aminobut-
2′-en-4′-ol (5) (0.07 g, 0.31 mmol) was dissolved in 
dichloromethane (15 mL) and cooled to 0 °C. 1,8-
Diazabicyclo[5.4.0]undec-7-ene (0.06 mL, 0.47 mmol) was 
added to the solution followed by trichloroacetonitrile (0.05 mL, 20 
0.47 mmol). The reaction mixture was then warmed to room 
temperature and stirred for 2 h. The reaction mixture was filtered 
through a short pad of silica gel and washed with diethyl ether 
(100 mL). The resulting filtrate was then concentrated to give 
allylic trichloroacetimidate 13, which was used without further 25 
purification. Allylic trichloroacetimidate 13 was then dissolved in 
dichloromethane (10 mL). (S)-COP-Cl 22 (0.023 g, 0.016 mmol) 
was added to the solution and the reaction mixture was stirred at 
room temperature for 72 h. Grubbs second generation catalyst 
(0.03 g, 0.03 mmol) was then added and the reaction mixture was 30 
heated under reflux for 24 h. The reaction mixture was cooled to 
room temperature and then filtered through a short pad of Celite 
and washed with diethyl ether (100 mL). Concentration of the 
filtrate, followed by flash column chromatography (petroleum 
ether/diethylether, 2:1) gave (3R)-1-(tert-butoxycarbonyl)-35 
2,3,6,7-tetrahydro-3-(2′,2′,2′- 
trichloromethylcarbonylamino)azepine (0.10 g, 92% over three 
steps) as a white solid. Chiral HPLC (Chiralcel IB column) 
analysis using 5% isopropanol in hexane as the elution solvent 
indicated 92% ee. [α]D26 –120.8 (c 1.0, CHCl3). All other 40 
spectroscopic data as previously reported above for 1-(tert-
butoxycarbonyl)-2,3,6,7-tetrahydro-3-(2′,2′,2′- 
trichloromethylcarbonylamino)azepine (4). 
 
(3S)-1-(tert-Butoxycarbonyl)-2,3,6,7-tetrahydro-3-(2′,2′,2′-45 
trichloromethylcarbonylamino)azepine 
The reaction was performed as described above, except using 
(2E)-N-(butyl-3-en-1-yl)-N-(tert-butoxycarbonyl)-1′-aminobut-2′-
en-4′-ol (5)  (0.06 g, 0.26 mmol) and (R)-COP-Cl (0.019 g, 0.013 
mmol). Purification by flash column chromatography (petroleum 50 
ether/diethylether, 2:1) gave (3S)-1-(tert-butoxycarbonyl)-
2,3,6,7-tetrahydro-3-(2′,2′,2′-
trichloromethylcarbonylamino)azepine (0.08 g, 84% over three 
steps) as a white solid. Chiral HPLC (Chiralcel IB column) 
analysis using 5% isopropanol in hexane as the elution solvent 55 
indicated 92% ee. [α]D24 +140.7 (c 0.7, CHCl3). All other 
spectroscopic data as previously reported above for 1-(tert-
butoxycarbonyl)-2,3,6,7-tetrahydro-3-(2′,2′,2′- 
trichloromethylcarbonylamino)azepine (4). 
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